Form 4: Tvardi Therapeutics Director Shaheen Wirk Reports Beneficial Ownership Changes Following Merger

Director Shaheen Wirk reports changes in beneficial ownership of Tvardi Therapeutics stock following the merger with Cara Therapeutics, including acquisitions of common stock and stock options.

Summary

• Shaheen Wirk, a director of Tvardi Therapeutics, reported changes in beneficial ownership following the merger between Cara Therapeutics and Tvardi Therapeutics.
• The report details the acquisition of 4,191 shares of common stock directly and 176,030 and 263,164 shares indirectly through Palkon Holdings, LLC and Palkon TT Holdings, LLC, respectively, all resulting from the merger.
• These acquisitions were in exchange for Series B Preferred Stock of Legacy Tvardi.
• Wirk also acquired a stock option for 2,011 shares of Tvardi Therapeutics common stock, converted from a Legacy Tvardi stock option.
• The reporting person disclaims beneficial ownership of shares held by the Palkon entities, except to any pecuniary interests therein.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the filing primarily reflects a procedural update following a merger. There are no explicit positive or negative implications for the company's performance.

Positives

• The director's increased stake in the company could signal confidence in the merged entity's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Similar filings are made by directors and officers of comparable companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals, reflecting their ownership positions and transactions in their respective companies' stock.

Stakeholder Impact

• The filing provides transparency to shareholders regarding insider ownership.
• The increased holdings of a director may be viewed positively by investors.

Key Dates

Keywords

Tvardi Therapeutics, Shaheen Wirk, Merger, Beneficial Ownership, Stock Option, Common Stock, Director, TVRD, Palkon Holdings, Palkon TT Holdings